国际皮肤性病学杂志    2003 29 (1): 13-16   ISSN: 2096-5540  CN: 32-1880/R   与细胞信号转导途径相关的抗银屑病药物作用靶点 李新宇, 郑家润 中国医学科学院、中国协和医科大学皮肤病研究所, 南京 210042 收稿日期 2002-01-22  修回日期 null  网络版发布日期 null 参考文献  [1] Ben-Bassat H,Klein BY.Inhibitors of tyrosine kinases in the treatment of psoriasis.Curt Pharm Des,2000,6(9);933-942. [2] Ben-Bassat H.Biological activity of tyrosine kinase inhibitors:novel agents for psoriasis therapy.Curr Opin Investig Drugs,2001,2(11):1539-1545. [3] Levitzki A.Protein tyrosine kinase inhibitors as novel therapeutic agents.Pharmacol Ther,1999,82(2-3);231-239. [4] Traxler P,Furet P.Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.Pharmacol Ther,1999,82(2-3):195-206. [5] Levitzki A.Signal-transduction therapy.A novel approach to disease management.Eur J Biochem,1994,226(1);1-13. [6] Jost M,Class R,Kari C,et al.A central role of Bcl-X(L)in the regulation of keratinocyte survival by autocrine EGFR ligands.J Invest Dermatol,1999,112(4);443-449. [7] Cuzzocrea S,McDonald MC,Mazzon E,et al.The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation.Am J Pathol,2000,157(1);145-158. [8] Powell TJ,Ben-Bassat H,Klein BY,et al.Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors.Br J Dermatol,1999,141(5);802-810. [9] Fong TA,Shawver LK,Sun L,et al.SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor(Flk-1/KDR)that inhibits tyrosine kinase catalysis,tumor vascularization,and growth of multiple tumor types.Cancer Res,1999,59(1);99-106. [10] Dvorak HF,Brown LF,Detmar M,et al.Vascular permeability factor/vascular endothelial growth factor,microvascular hyperpermeability,and angiogenesis.Am J Pathol,1995,146(5);1029-1039. [11] Hasan J,Jayson GC.VEGF antagonists.Expert Opin Biol Ther,2001,1(4);703-718. [12] Bosco MC,Curiel RE,Zea AH,et al.IL-2 signaling in human monocytes involves the phosphorylation and activation of p59hck.J Immunol,2000,164(9);4575-4585. [13] Kamens JS,Ratnofsky SE,Hirst GC.Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection.Curt Opin Investig Drugs,2001,2(9):1213-1219. [14] Lin P,Baldassare JJ,Voorhees JJ,et al.Increased activation of Ras in psoriatic lesions.Skin Pharmacol Appl Skin Physiol,1999,12(1-2);90-97. [15] Hirano T.Interleukin 6 and its receptor:ten years later.Int Rev Immunol,1998,16(3-4);249-284. [16] Jackson M,Howie SE,Weller R,et al.Psoriatic keratinocytes show reduced IRF-1 and STAT-1 alpha activation in response to gamma-IFN.FASEB J,1999,13(3);495-502. [17] Lewis AJ,Manning AM.New targets for anti-inflammatory drugs.Curr Opin Chem Biol,1999,3(4);489-494. [18] Haase I,Hobbs RM,Romero MR,et al.A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis.J Clin Invest,2001,108(4);527-536. [19] Murdoch C,Finn A.Chemokine receptors and their role in inflammation and infectious diseases.Blood,2000,95(10);3032-3043. 通讯作者: